EuroPCR 2022 | Renal denervation increases long-term time in target blood pressure range compared with sham control

Most hypertensive patients do not reach target blood pressure level ranges despite optimal medical treatment. Regardless anti-hypertensive medication, patients undergoing radiofrequency renal denervation have seen significant improved control of blood pressure, with relevant clinical impact.

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

One of the outcomes we look at in chronic diseases such as hypertension and diabetes is time in target range (TTR) looking at how much time patients spend within a target BP range. In the context of hypertension, TTR has been shown to be an independent predictor of cardiovascular event reduction. 

This study looked at 3-year outcomes of the randomized sham controlled SPYRAL HTN-ON MED assessing TTR (target blood pressure at office/ambulatory 140mmHg) in patients receiving renal denervation vs. sham control. 

80 patients were randomized, mean age 53.9, mostly men (87%) with average 24hr systolic blood pressure 152 ±7 mmHg, with 93% adherence to medication in the SHAM group.

Prior studies had shown that patients with renal denervation had seen significant reduction of target blood pressure within 24 hrs. (Δ -10.0 mmHg, P=0.04). This study showed higher TTR for both office and ambulatory blood pressures (<140mmHg) at study kickoff and later at 6, 12, 24 and 36 month followup (non-significantly). 

Read also: EuroPCR 2022 | ASTRO TAVR: Should we treat post TAVR Strokes with Neurointervention?

When looking at hypertension measurements, there was lower severe hypertension (≥180mmHg) in the renal denervation branch (3% vs 8.8%). When combining office 140 and ambulatory BPs 130 mmHg, TTR accuracy improved significantly. 

Conclusions

Patients undergoing renal denervation presented significantly higher TTR. We should look at the clinical implications of higher TTR with renal denervation, which helps reduce cardiovascular events. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: Renal Denervation Increases Long-term Time in Target Blood Pressure Range Compared with Sham Control (SPYRAL-HTN on-meds).

Source: Presented by Kandzari, D. E. en EuroPCR 2022, París, Francia.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

A New Asymptomatic Carotid Stenosis Paradigm? CREST-2 Trial Unified Results

Severe asymptomatic carotid stenosis continues to be controversial seeing the optimization of intensive medical therapy (IMT) and the availability lower periprocedural risk revascularization techniques....

Impact of Baseline Systolic Blood Pressure on Blood Pressure Changes Following Renal Denervation

Renal denervation (RDN) is a guideline-recommended therapy to reduce blood pressure in patients with uncontrolled hypertension, although uncertainties remain regarding which factors best predict...

Hypertriglyceridemia as Key Factor to Abdominal Aortic Aneurysm Development and Rupture: Genetic and Experimental Evidence

Abdominal aortic aneurysm (AAA) is a deadly vascular disease with no effective drug treatment, and risk of rupture reaching up to 80%. Even though...

Atrial Fibrillation and Chronic Kidney Disease: Outcomes of Different Stroke Prevention Strategies

Atrial fibrillation (AF) affects approximately 1 in every 4 patients with end-stage renal disease (ESRD). This population carries a high burden of comorbidities and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...